We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NIDA Supports Development of Combined Anti-Heroin and HIV Vaccine
News

NIDA Supports Development of Combined Anti-Heroin and HIV Vaccine

NIDA Supports Development of Combined Anti-Heroin and HIV Vaccine
News

NIDA Supports Development of Combined Anti-Heroin and HIV Vaccine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NIDA Supports Development of Combined Anti-Heroin and HIV Vaccine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dr. Gary R. Matyas has been selected the 2012 recipient of the NIDA Avant-Garde Award for Medications Development.

Matyas proposes to develop an effective, safe and easily manufactured combination anti-heroin/HIV vaccine that could treat heroin addiction while at the same time prevent HIV infection in those receiving the vaccine.

Matyas will receive $1,000,000 per year for five years to support his research. He works at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, M.d.

The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, announced the award.

"This highly innovative dual-vaccine model would simultaneously address the intertwined epidemics of heroin abuse and HIV," said NIDA Director Dr. Nora D. Volkow.

Dr. Volkow continued, "This is precisely the type of ground-breaking research NIDA's Avant-Garde program was designed to support. The implications for public health are enormous."

The proposal stems from an existing research collaboration between NIDA and the U.S. Military HIV Research Program, part of the WRAIR. In 2010, the two organizations entered into an agreement to create a combination anti-heroin/HIV vaccine.

The goal was to build upon previous preclinical research indicating that hapten-based anti-drug vaccines - in which a small molecule chemically similar to a drug of abuse (hapten) is bound to a protein carrier to induce an immune response - showed promise against a variety of abused drugs, including heroin.

As a result of this collaboration, the heroin component of a combination anti-heroin/HIV vaccine has now been created and is ready for optimization and advanced preclinical testing. This current grant award will support this next phase of research and development.

The award will be administered through the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and work done in collaboration with the U.S. Military HIV Research Program and NIDA.

"Heroin use is strongly associated with a high risk of HIV infection and represents an increasingly important worldwide health problem," stated Matyas. "The possibility of creating a combination heroin-HIV vaccine provides an important opportunity to address both a unique treatment for heroin abuse as well as continuing the quest to develop an effective preventive HIV vaccine."

This research competition is an extension of NIDA's successful Avant-Garde Award for Innovative HIV/AIDS Research (http://www.drugabuse.gov/about-nida/organization/offices/office-nida-director-od/aids-research-program-arp/avant-garde-award-hivaids-research), now in its fifth year.

Both competitions are intended to stimulate high-impact research that may lead to opportunities for the prevention and treatment of drug abuse.

For further information about NIDA's Avant-Garde Award for Medications Development, please visit (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-12-010.html).

A statement from the NIDA Director on NIDA's commitment to vaccine development can be found at (http://www.nida.nih.gov/about/welcome/Messagenicvax2.html).

Matyas is funded under grant number: DA034787.

Advertisement